AstraZeneca PLC (AZN)vsSomalogic Inc (SLGC)
AZN
AstraZeneca PLC
$184.74
-1.40%
HEALTHCARE · Cap: $287.11B
SLGC
Somalogic Inc
$9.89
0.00%
HEALTHCARE · Cap: $396.23M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 71775% more annual revenue ($58.74B vs $81.72M). AZN leads profitability with a 17.4% profit margin vs -159.5%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SLGC
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.0%
Fair Value
$214.34
Current Price
$184.74
$29.60 discount
Margin of Safety
-12.9%
Fair Value
$1.86
Current Price
$9.89
$8.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -23.7% — below average capital efficiency
Revenue declined 47.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : SLGC
SLGC has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : SLGC
The primary concerns for SLGC are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while SLGC is a turnaround play — different risk/reward profiles.
SLGC carries more volatility with a beta of 1.64 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 29/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Somalogic Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
SomaLogic Inc. (SLGC) is a pioneering biotechnology company specializing in protein biomarker discovery and analysis, harnessing its proprietary SomaScan® platform to provide insights that advance precision medicine. By utilizing an extensive protein library, the company aims to develop sophisticated diagnostics and therapeutic applications across various health conditions, including cancer, cardiovascular diseases, and metabolic disorders. SomaLogic is positioned at the forefront of the biomarker industry, driving innovation in research and clinical settings while forming strategic partnerships to expand its reach and enhance the adoption of its technologies. With a strong focus on data-driven health solutions, SomaLogic is committed to improving patient outcomes and enabling personalized therapeutic strategies.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?